Metrics as of 10/15/2026, 05:21 AM (Berlin time), refresh in progress.
Atara Biotherapeutics Stock
Atara Biotherapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Anhco Nguyen
- Employees
- 10
- Market cap
- $86 M
- IPO
- 16/10/2014
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral…
Atara Biotherapeutics stock: price history
1D
+2.7%
1W
+2.0%
1M
+3.4%
6M
+82.4%
YTD
-47.2%
1Y
-34.6%
2Y
+17.3%
5Y
-97.5%
10Y
-97.6%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~5% stronger price swings than usual
Ask the agents about Atara Biotherapeutics
Analyst assessment of Atara Biotherapeutics
PRICE TARGET LOW
US$13.00
CONSENSUS
US$13.00
MEDIAN
US$13.00
PRICE TARGET HIGH
US$13.00
0
STRONG BUY
4
BUY
7
HOLD
2
SELL
0
STRONG SELL
13
TOTAL · Hold
As of: 18/05/2026
Atara Biotherapeutics stock metrics
P/E
-8.1
P/B
-3.88
EV/EBITDA
-6.77
RETURN ON EQUITY
13.1%
NET MARGIN
-767.3%
DEBT/EQUITY
-0.27
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
66.6%
FLOAT SHARES
6,000,665
AVG. DAILY VOLUME (30D)
45,603
Insider transactions (SEC)
Cherry Brian N
Nguyen AnhCo
Redmile Group, LLC
Redmile Group, LLC
Cherry Brian N
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Atara Biotherapeutics stock
What does Atara Biotherapeutics do?
Atara Biotherapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Anhco Nguyen, the company employs around 10 people.
The IPO was on 16/10/2014; the stock trades on NASDAQ under the ticker ATRA.
What do analysts say about Atara Biotherapeutics stock?
13 analysts rate the stock, the consensus is Hold (as of 18/05/2026).
The average price target is US$13.00, ranging from US$13.00 to US$13.00, with a median of US$13.00.
This is an external assessment, not a statement by Market Jury.
When does Atara Biotherapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Atara Biotherapeutics pay a dividend?
No, Atara Biotherapeutics currently does not pay a dividend.
Which stocks are comparable to Atara Biotherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Atara Biotherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Atara Biotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.